Objective: To determine the relation between time to surgery (TTS) after neoadjuvant chemoradiotherapy (nCRT) and pathologically complete response (pCR), surgical outcome, and survival in patients with esophageal cancer. Background: Standard treatment for potentially curable esophageal cancer is nCRT plus surgery after 4 to 6 weeks. In rectal cancer patients, evidence suggests that prolonged TTS is associated with a higher pCR rate and possibly with better survival. Methods: We identified patients treated with nCRT plus surgery for esophageal cancer between 2001 and 2011. TTS (last day of radiotherapy to day of surgery) varied mainly for logistical reasons. Minimal follow-up was 24 months. The effect of TTS on pCR rate, postoperative complications, and survival was determined with (ordinal) logistic, linear, and Cox regression, respectively. Results: In total, 325 patients were included. Median TTS was 48 days (p25-p75 = 40-60). After 45 days, TTS was associated with an increased probability of pCR [odds ratio (OR) = 1.35 per additional week of TSS, P = 0.0004] and a small increased risk of postoperative complications (OR = 1.20, P < 0.001). Prolonged TTS had no effect on disease-free and overall survivals (HR = 1.00 and HR = 1.06 per additional week of TSS, P = 0.976 and P = 0.139, respectively). Conclusions: Prolonged TTS after nCRT increases the probability of pCR and is associated with a slightly increased probability of postoperative complications, without affecting disease-free and overall survivals. We conclude that TTS can be safely prolonged from the usual 4 to 6 weeks up to at least 12 weeks, which facilitates a more conservative wait-and-see strategy after neoadjuvant chemoradiotherapy to be tested. ) at the Erasmus MC-University Medical Center Rotterdam (a tertiary referral hospital in Rotterdam, The Netherlands). Patients who did not receive at least 80% of planned nCRT or who received a different nCRT regimen were excluded. Also, patients with irresectable tumors (cT4b) and/or disseminated disease (M1) were excluded.
R ecent studies show that, in patients with potentially curable esophageal or esophagogastric junction cancer, the addition of neoadjuvant chemoradiotherapy (nCRT) to surgery improves locoregional control and long-term survival. 1, 2 Therefore, nCRT plus surgery has become the standard of care for patients with potentially curable esophageal or junctional cancer in many countries.
Reasons for prolonged time to surgery (TTS) after nCRT include patients' malnutrition or poor physical status, comorbidities such as infections and cardiopulmonary problems, and logistical problems such as hospital bed and operating room availability.
Tumor response to neoadjuvant therapy is classified in several tumor regression grading (TRG) systems. [3] [4] [5] [6] A pathologically complete response (pCR; ie, no viable tumor cells found in the resection specimen) has been recognized as a valuable prognostic factor for long-term survival. 3, [7] [8] [9] [10] It remains unclear, however, whether prolonged TTS has an impact on pCR rate, on short-term surgical outcome and on long-term survival.
Theoretically, prolonged TTS might increase pCR rate and possibly improve disease-free survival (DFS) because of a prolonged effect of nCRT. Conversely, prolonged TTS might lead to residual tumor outgrowth, increased difficulty of surgical resection with a higher postoperative complication rate, and possibly a worse overall survival (OS).
In rectal cancer patients, several studies have shown that prolonged TTS probably increases the percentage of pathologically complete responders. [11] [12] [13] [14] [15] [16] [17] [18] Perioperative morbidity and mortality, DFS and OS, seem less clearly correlated with TTS. 12, 13, [15] [16] [17] [18] [19] [20] [21] [22] Comparable studies in esophageal cancer patients have shown no effect of TTS on pCR rate and no (or little) effect on DFS. 23, 24 We aimed to investigate the impact of TTS after nCRT on pCR rate, short-term surgical outcome, and DFS and OS in a cohort of patients with potentially curable esophageal or junctional cancer, who underwent neoadjuvant chemoradiotherapy according to CROSS 2 followed by surgical resection.
Treatment and Pathological Assessment
The neoadjuvant treatment regimen has been described before in detail. 2 Esophagectomy was planned 4 to 6 weeks after completion of nCRT. The resection specimens (primary tumor and all resected lymph nodes) were processed according to a standardized protocol. 26 The TRG was scored with the modified Mandard scoring system as reported by Chirieac et al. 3, 4 A microscopically radical resection (R 0 ) was defined as a tumor-free resection margin of 1 mm or more.
Follow-up and Data Collection
Clinical, surgical, and histopathological characteristics were retrieved from prospectively maintained institutional databases. TTS was determined as the interval between the last day of radiotherapy and the day of surgery. After surgery, patients were routinely followed; every 3 months during the first postoperative year, every 6 months during the second postoperative year, and yearly until the fifth postoperative year. During follow-up, diagnostic investigations were performed only when recurrence was suspected clinically. Recurrences were scored at the time of first failure. Survival was determined using hospital records and municipal registers.
Surgical Outcome
Surgical outcome was described by duration of operation in minutes, intraoperative blood loss in milliliters, and length of hospital stay in days. Postoperative complications were categorized according to the Clavien-Dindo classification, 27,28 a postoperative complication ranking system: grade 0-no complications; grade Icomplications requiring no or minimal (nonpharmacological) treatment; grade II-complications requiring pharmacological treatment; grade III-complications requiring surgical, endoscopic, or radiological intervention; grade-IV-life-threatening complications requiring intensive care unit-level care; and grade V-postoperative death.
Potential Delay-Related Confounders
To correct for the possibility that variations in TTS were not only caused by random logistical difficulties but also by patientrelated characteristics (i.e. intentionally longer TTS in more vulnerable patients), effects of TTS on pCR and on surgical outcome were adjusted for 3 potential delay-related confounders. First, this was the Charlson comorbidity index 29 at diagnosis, an indicator of comorbidity. For this index, each condition present at diagnosis is assigned a standard score of 1, 2, 3, or 6 (determined by the estimated risk of dying from this condition). The total sum per patient is predictive for mortality. Second, the Karnofsky performance status 30, 31 at the end of nCRT, an indicator of general well-being. The scale ranges from 100 (normal health) to 0 (death). A score of 90 indicates minor signs and/or symptoms of disease, 80 indicates mild signs and/or symptoms of disease, etc. Third, weight loss during nCRT, defined as the difference in body weight (in kilograms) between the start of the first cycle of chemotherapy and the start of the fifth cycle of chemotherapy. Weight gains were set to zero loss.
Statistical Analysis
Baseline data were described as medians with the interquartile range in case of continuous variables and as frequencies with percentages in case of categorical variables. Missing baseline data were imputed with a single imputation technique based on correlations with relevant baseline variables and outcome. TTS was truncated at 5% and 95% to reduce leverage effects of outliers. The effect of TTS on pCR and on surgical outcome was determined using univariable and multivariable logistic regression. Nonlinearity of the effect of TTS was assessed with restricted cubic splines (3 knots). 32 To correct for the possibility that TTS was intentionally longer in more vulnerable patients, the effects of TTS on surgical outcome was adjusted in multivariable regression analysis for the 3 potential delay-related confounders together with surgical approach (adjusted odds ratio, aOR). Subsequently, the effects of pCR and TTS on DFS and OS were assessed using Cox regression with adjustment for the 3 potential delay-related confounders alone and in combination with postoperative complications (adjusted hazard ratio, aHR).
RESULTS

Patient-and Treatment-Related Characteristics
In total, 325 patients with potentially curable esophageal or junctional cancer were included who underwent nCRT according to CROSS 2 followed by resection between February 2001 and December 2011. Fifty-one included patients participated in the phase II trial, 25 157 patients participated in the multimodality arm of the randomized phase III trial, 2 and 117 patients were treated with nCRT followed by resection as standard therapy in the period after completion of the phase III trial. In total, 344 patients completed nCRT within the 3 cohorts. Of these, 4 patients did not undergo surgery (primarily due to patient preferences) and 15 additional patients did not undergo resection (due to disease progression).
Clinical, surgical, and histopathological characteristics of included patients are summarized in Table 1 . Median age at diagnosis was 60 years. The majority of patients were male (78%), had an adenocarcinoma (76%), and were clinically staged as cT3 (77%), cN1 (63%). Before truncation, TTS ranged from 18 to 291 days, with a median of 48 days (interquartile range: 40-60 days), as also shown in Figure 1 . Median TTS in irresectable patients was 46 days (interquartile range: 40-61 days), which was similar to TTS in resected patients (P = 0.99). Surgical resection was performed regularly via both transhiatal approach (48%) and transthoracic approach (50%). Median duration of operation was 368 minutes, median volume of intraoperative blood loss was 900 mL, and median length of hospital stay was 14 days. Postoperative complications requiring pharmacological, interventional, or surgical treatment (≥ grade-II) were reported in 55% of patients. Postoperative in-hospital mortality was 4%. Histopathological staging showed frequent ypT0 and ypT3 stages (34% and 32%, respectively), whereas ypN0 was the most frequent nodal stage (68%). A pCR (TRG1) was found in 28% of patients. The microscopically radical resection rate (R 0 ) was 93%.
The potential delay-related confounders are summarized in Table 2 . The majority of patients had a pretreatment Charlson comorbidity index of 0 (75%) and a Karnofsky performance score at the end of nCRT of 90 (64%). Median weight loss during nCRT was 1 kg (p25-p75: 0-3).
Effect of TTS on pCR
Median TTS was 48 days (p25-p75: 40-60 days, p5-p95: 18-83 days). The association of TTS with pCR was nonlinear (P = 0.025). After approximately 45 days ( Supplementary Fig. 1 , available at http://links.lww.com/SLA/A672), additional TTS was associated with an increased probability of pCR (OR = 1.35 per additional week after 45 days, P = 0.0004).
In itself a pathologically complete response was associated with a significantly better DFS and OS (HR= 0.29, P < 0.0001 and 0.44, P < 0.0001, respectively). The effect of pCR on OS was sustained after correction for the 3 potential delay-related confounders (aHR = 0.44, P < 0.0001). ||ypT and ypN-stage: pathological T-stage and pathological N-stage in the resection specimen following neoadjuvant chemoradiotherapy, according to UICC TNM Cancer Staging, 7th edition. * * Tumor regression grade was defined as: TRG1: no residual tumor cells found; TRG2: 1%-10% residual tumor cells; TRG3: 11%-50% residual tumor cells; TRG4: >50% residual tumor cells.
† †R 0 was defined as a tumor-free resection margin ≥ 1 mm. R 1 was defined as a macroscopically radical resection, with a microscopically tumor-free resection margin < 1 mm. FIGURE 1. Distribution of TTS (before truncation) in 340 patients who completed neoadjuvant chemoradiotherapy according to CROSS 2 and underwent surgery for potentially curable esophageal or junctional cancer, 15 of these patients were irresectable due to disease progression, whereas 325 patients underwent resection. 29 an indicator of comorbidity. Each condition present at diagnosis is assigned a standard score of 1, 2, 3, or 6 (determined by the estimated risk of dying from this condition). The total sum per patient is predictive for mortality.
‡Karnofsky performance status 30 , 31 an indicator of general well-being. The scale ranges from 100 (normal health) to 0 (death). A score of 90 indicates minor signs and/or symptoms of disease, 80 indicates mild signs and/or symptoms of disease, etc. §Weight loss during nCRT was defined as the difference in body weight (in kilograms) between the start of the first cycle of chemotherapy and the start of the fifth cycle of chemotherapy. Weight gains were set to zero loss.
Effect of TTS on Short-term Surgical Outcome
The effect of TTS on short-term surgical outcome was reasonably linear (nonlinearity, P = 0.920). Increased TTS was associated with prolonged duration of operation (12 minutes per additional week of TTS, P < 0.001), prolonged length of hospital stay (1.55 day per additional week of TTS, P = 0.006), and more severe postoperative complications (OR 1.20 per additional week of TTS, P < 0.001).
No association was found with intraoperative blood loss (−3 mL per additional week of TTS, P = 0.898). However, these associations were partly explained by the 3 potential delay-related confounders together with surgical approach. After adjustment, the effects were reduced for duration of operation (6 minutes per additional week of TTS, P = 0.031), length of hospital stay (1.03 days per additional week of TTS, P = 0.071), and for postoperative complications (aOR 1.10 per additional week of TTS, P = 0.132, Table 3 ).
Effect of TTS on Survival
The effect of TTS on DFS and OS was reasonably linear (nonlinearity, P = 0.566). Increased TTS was not associated with DFS (HR = 1.00, P = 0.976; aHR = 0.98, P = 0.620), nor with OS (HR = 1.06, P = 0.139; aHR = 1.03, P = 0.465, Table 4 ).
DISCUSSION
Results show that prolonged TTS, beyond 45 days after completion of nCRT, significantly increased the probability of pCR. Longer TTS was also associated with a small increased risk of postoperative complications. Furthermore, pCR in the resection specimen was associated with significantly improved DFS. However, prolonged TTS (with increased probability of pCR) was not associated with improved DFS.
Although prolonged TTS was associated with an increased pCR rate, DFS was not accordingly improved. The comparable DFS between patients with shorter and longer TTS implies that their disease is biologically similar, despite differences in pCR rate. The increase in pCR after prolonged TTS is attributed to patients who presumably would have been noncomplete responders at shorter TTS. Interestingly, these patients, who become pathologically complete responders relatively late after completion of nCRT, do not contribute to an improved DFS after prolonged TTS. This can be explained if "late complete responders" would already behave as biologically complete responders at shorter TTS, despite a pathologically noncomplete response in their resection specimens. Therefore, the (minimal) residual disease found at histological examination after shorter TTS in these late complete responders is presumed to be biologically nonrelevant. We hypothesize that prolonged TTS does not truly improve the biological pCR rate, but that prolonged TTS simply allows for a more precise histopathological distinction between viable residual tumor cells and biologically nonrelevant tumor cell debris by the pathologist.
In this cohort, prolonged TTS was significantly associated with a prolonged duration of operation, a prolonged length of hospital stay, and increased postoperative complications. However, these associations were partly explained by the 3 potential delay-related confounders, that is, Charlson comorbidity index 29 at diagnosis, Karnofsky performance status 30, 31 at the end of nCRT, and weight loss during nCRT (besides surgical approach; Table 3 ). These potential confounding factors were chosen to reflect the overall condition of patients at the end of nCRT, which might have influenced the surgeons' decision to delay surgical resection after nCRT, independent of logistical planning. Therefore, these results indicate that the association of prolonged TTS with negative short-term surgical outcome and increased postoperative complications is partly the result of an intentionally prolonged TTS in patients with a worse overall condition at the end of nCRT and that prolonged TTS has at most a small association with short-term surgical outcome and postoperative complications.
Two previous studies investigated the association between TTS and surgical and oncological outcome in patients with esophageal cancer. Both studies did not find a correlation with pCR rate. 23, 24 This discrepancy with the present study might be related to the heterogeneity of nCRT protocols used in both previous studies. In our cohort, all patients completed the same nCRT protocol, and in all patients there was a similar initial intention to undergo surgery after 4 to 6 weeks, possibly allowing for a clearer delineation of the effect of TTS on pCR rate. Also, the present study investigated the association between TTS and pCR in all patients using logistic regression, resulting in more power to detect subtle effects as compared to subgroup analyses. Last, this study focused on the association between TTS and DFS, which was lacking in the study by Kim and colleagues. 24 Currently, controversy exists concerning the management of cancer patients with a clinically complete response after neoadjuvant therapy. For rectal cancer patients, more conservative strategies have already been proposed and tested in clinically complete responders. [33] [34] [35] [36] The goal of these wait-and-see approaches is organ preservation and overall reduction in treatment-related morbidity and mortality. However, it has remained difficult to clinically distinguish truly complete responders from nearly complete responders. Patients belonging to the latter group might be incorrectly identified as clinically complete responders and could thus be exposed to potentially harmful disease progression during the wait-and-see period. For esophageal cancer, the challenge to distinguish complete from nearly complete responders seems even more difficult. [37] [38] [39] [40] However, if surgery can be safely postponed beyond the usual 4 to 6 weeks, without negatively affecting oncological outcome as suggested in the present study, more time is allowed to identify noncomplete responders. Such a strategy would not focus on distinguishing complete from noncomplete responders at a single instance, but would rather use intense surveillance, with targeting of the mucosa and submucosa 41 during repeated instances, for the detection of residual or recurrent disease. Thereby, possibly allowing more time to differentiate between truly complete responders and noncomplete responders.
Limitations of the Study
The first limitation is that this study was a retrospective analysis. However, all parameters in this study were collected prospectively. Furthermore, all 3 cohorts used the same neoadjuvant CROSS regimen and all 3 cohorts had a similar intention to perform surgery at 4 to 6 weeks after completion of nCRT. The second limitation of this study is that the number of patients with a TTS beyond 10 weeks was relatively small. Therefore, a subtle effect of TTS on DFS and OS cannot be excluded in patients with a TTS beyond 10 weeks.
CONCLUSIONS
In patients with potentially curable esophageal or junctional cancer, prolonged TTS (beyond 45 days) after neoadjuvant chemoradiotherapy increases the probability of a pathologically complete response, without improving DFS and OS. It might also slightly increase the probability of postoperative complications, which can be partly explained by intentional postponement of surgery in some high-risk patients with worse overall condition. We hypothesize that prolonged TTS allows for more accurate determination of histopathological response due to continued disintegration of nonviable cells in some patients, without affecting actual prognosis after neoadjuvant chemoradiotherapy. We conclude that TTS can be safely prolonged from the usual 4 to 6 weeks up to at least 12 weeks, which facilitates a more conservative wait-and-see strategy after neoadjuvant chemoradiotherapy to be tested. didn't show any survival benefits or disease-free survival benefits in the delayed group. So, what are your arguments for waiting longer after chemoradiotherapy? Shouldn't we go directly to surgery after 6 weeks?
Response From J. Shapiro, J. van Lanschot (Rotterdam, Netherlands):
Thank you for your question. I don't necessarily propose to wait longer, although I think you would obtain a clearer image in the resected specimen. I think that this study adds to the evidence that if you have a reason to wait, then you can do this safely for up to 12 weeks after completion of neoadjuvant therapy. It is difficult to test how good our correction of the effect of time to surgery was using the patients' condition at the end of neoadjuvant therapy, although the patients' condition is considered a valid confounder since it confounded both time to surgery and our outcome-in this case, surgical outcome. We tested for the impact of the 3 potential delay-related factors. I have to say that weight loss during neoadjuvant therapy was borderline significant. The other 2 were significant in their impact on both the time to surgery and on postoperative outcomes. However, it remains a valid point that surgery might become more difficult, if you wait longer.
